Effect of interleukin-17A inhibitor in Japanese patients with psoriatic arthritis compared with tumor necrosis factor-alpha inhibitor.

Takuya IzumiyamaYu MoriItsuki OizumiSoshi HamadaHiroaki KurishimaHitoshi TeruiRyoko Omori-ShimadaKenshi YamasakiEiji Itoi

Published in: Journal of orthopaedic surgery (Hong Kong) (2021)

Our study presented that IL-17Ai had treatment effects comparable to TNFi. IL-17Ai might have the potential to become an alternative to the previous drug, but more large-scale studies are expected.

Keyphrases

artificial intelligence
rheumatoid arthritis
case control
combination therapy
deep learning
risk assessment
climate change
adverse drug
electronic health record